SCHEMBL608506

SCHEMBL608506

Cc1ccc(C=CC(=O)C=C(O)C=Cc2ccc(C)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOS P01100 2/20 1.00
JUN P05412 2/20 1.00
GSK3B P49841 8/20 0.70
BACE1 P56817 8/20 0.70
TLR9 Q9NR96 1/20 0.70
MAPT P10636 4/20 0.56
ALDH1A1 P00352 2/20 0.56
CYP3A4 P08684 1/20 0.56
HPGD P15428 1/20 0.56
RAB9A P51151 2/20 0.54
KMT2A Q03164 1/20 0.54
CYP1B1 Q16678 1/20 0.51
TRPM8 Q7Z2W7 1/20 0.51
MAOA P21397 2/20 0.50
MAOB P27338 2/20 0.50
CYP2D6 P10635 2/20 0.50
CYP2C9 P11712 2/20 0.50
F3 P13726 2/20 0.50
PLIN1 O60240 1/20 0.50
LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4442364 1.00 FOS (1.00) FOSJUNGSK3BBACE1TLR9
SCHEMBL15290855 0.93 FOS (0.87) FOSJUNGSK3BBACE1TLR9
SCHEMBL10061357 0.87 FOS (0.77) FOSJUNGSK3BBACE1TLR9
SCHEMBL5598705 0.86 JUN (0.74) FOSJUNMAPTALDH1A1CYP3A4
SCHEMBL5598702 0.86 JUN (0.74) FOSJUNMAPTALDH1A1CYP3A4
SCHEMBL9162036 0.82 MAPT (0.76) FOSJUNMAPTALDH1A1CYP3A4
SCHEMBL11999791 0.82 MAPT (0.76) FOSJUNMAPTALDH1A1CYP3A4
SCHEMBL609968 0.82 GSK3B (1.00) FOSJUNGSK3BBACE1TLR9
SCHEMBL609967 0.82 GSK3B (1.00) FOSJUNGSK3BBACE1TLR9
SCHEMBL608387 0.82 MAPT (0.75) FOSJUNGSK3BBACE1TLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040976-A1 SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2012-02-16 US disclosed
US-20090263492-A1 Diagnostic Methods and Genetic Markers for Alzheimer Disease HUMAN BIOMOLECULAR RESEARCH INSTITUTE 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090263492-A1 Diagnostic Methods and Genetic Markers for Alzheimer Disease CHAT, SLC18A3, GAP43 FOS 4099/4885JUN 4432/4885GSK3B 2770/4885
US-20120040976-A1 SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE L1CAM, LY96, GMFG FOS 4116/4885JUN 4222/4885GSK3B 3394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.